Cost-effectiveness of various maintenance therapies based on mutation status following first-line treatment of primary epithelial ovarian cancer in the United States

被引：0
作者：
Penn, Courtney Alexis [1 ]
Wong, Melissa Spring [2 ]
Walsh, Christine [2 ]
机构：
[1] Cedars Sinai Med Ctr, Womens Canc Program, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
GYNECOLOGIC ONCOLOGY | 2020年 / 159卷 / 02期
关键词：
D O I：
10.1016/j.ygyno.2020.07.050
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18
引用
收藏
页码：E14 / E14
页数：1
相关论文
共 50 条
[31]   Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States [J].
Holly Guy ;
Lydia Walder ;
Mark Fisher .
PharmacoEconomics, 2019, 37 :391-405
[32]   Cost-effectiveness of new therapies in first-line treatment of advanced melanoma for patients with independent BRAF mutation status from a Brazilian private payer perspective. [J].
Matteucci, Christina ;
Lima, Joao P. S. D. N. ;
Bernardino, Graziela ;
Oliveira, Ana Paula ;
Maia, Daniela Galdeano .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[33]   The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales [J].
Tappenden, P. ;
Jones, R. ;
Paisley, S. ;
Carroll, C. .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (17) :2487-2494
[34]   Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis [J].
Zhang, Peng-Fei ;
Wen, Feng ;
Wu, Qiu-Ji ;
Li, Qiu .
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (14) :1021-1030
[35]   Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States [J].
Criss, Steven D. ;
Mooradian, Meghan J. ;
Watson, Tina R. ;
Gainor, Justin F. ;
Reynolds, Kerry L. ;
Kong, Chung Yin .
JAMA NETWORK OPEN, 2019, 2 (09)
[36]   Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the United States [J].
Berling, M. ;
Chaudhary, M. A. ;
Yuan, Y. ;
Varol, N. ;
Dale, P. ;
Testa, E. ;
Klint, J. ;
Lee, A. ;
Lubinga, S. J. ;
Penrod, J. R. .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) :S15-S16
[37]   Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA [J].
David Elsea ;
Dominic Muston ;
Lin Fan ;
Adela Mihai ;
Yang Meng ;
Adam Kasle ;
Matthew Monberg .
Targeted Oncology, 2023, 18 :531-541
[38]   Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA [J].
Elsea, David ;
Muston, Dominic ;
Fan, Lin ;
Mihai, Adela ;
Meng, Yang ;
Kasle, Adam ;
Monberg, Matthew .
TARGETED ONCOLOGY, 2023, 18 (04) :531-541
[39]   Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States [J].
Li, Andong ;
Wu, Meiyu ;
Xie, Ouyang ;
Xiang, Heng ;
Meng, Kehui ;
Tan, Chongqing ;
Wang, Long ;
Wan, Xiaomin .
FRONTIERS IN IMMUNOLOGY, 2024, 15
[40]   Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States [J].
Yunusa, Ismaeel ;
Love, Bryan L. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (04) :635-644
12345